Evaluation of the Potential Association Between 5a-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02873117
• Date of registration: 16/08/2016
• Prospective Registration: No
• Primary sponsor: Rennes University Hospital
• Public title: Evaluation of the Potential Association Between 5a-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers CANARI
• Scientific title: Evaluation of the Potential Association Between 5a-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers
• Date of first enrolment: December 2014
• Target sample size: 5154
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02873117
• Study type: Observational

Countries of recruitment

France

Key inclusion & exclusion criteria

Inclusion Criteria:

- Men with a reimbursement of any pharmacologic treatment patented for symptomatic
benign prostate hyperplasia between January 1st 2010 and December 31st 2011,
affiliated to French health system and living in Brittany, France.

Exclusion Criteria:

- Prostate cancer with a date of diagnosis before December 31st, 2011, patients enrolled
in surveillance program with scheduled prostate biopsy, patients not affiliated to
French health system.



Age minimum: N/A
Age maximum: N/A
Gender: Male

Health Condition(s) or Problem(s) studied

Benign Prostate Hyperplasia

Intervention(s)

Other: Prostate biopsy, prostatectomy or prostate resection

Primary Outcome(s)

High grade (Gleason >= 7) prostate cancer [Time Frame: Day 1]

Secondary ID(s)

35RC13_8911_CANARI

Source(s) of Monetary Support

Please refer to primary and secondary sponsors